AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06655532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Patients allocated to this arm will receive the usual care plus supervised aerobic and moderate to high-intensity strength training twice weekly.
Study NCT06655532 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Patients allocated to this arm will receive standard medical treatment plus explicit recommendations for 12-week home-based moderate-intensity aerobic and strength training. They will also receive a weekly phone call and an in-person monthly visit to monitor exercise training performance.
Study NCT05906784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group acupuncture
Description: Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. Acupuncture treatments will include a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Acupuncture points will be selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
Study NCT05906784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Group Medical Visits
Description: IGMV sessions will be weekly for 90 minutes in a group meeting space. Sessions will start with a check-in where participants can share their emotions, thoughts, hopes, and fears related to their health and pain and provide updates since the last session. Group sessions will be led by a primary care provider and a health educator and will include psychosocial support, tools for pain self-management, and psychoeducation for pain management. Invited experts will provide information on educational topics, including neurobiology of pain, medication safety, and connections between mood and pain, as well as participatory activities such as therapeutic movement or mindfulness practice.
Study NCT05085873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate injection
Description: * Induction dosage : 60 mg/kg by direct intravenous injection.~* Continuous dosage : 45 mg/kg/h by continuous intravenous injection.~* Additional dosage if the Richmond Agitation Sedation Scale (RASS) score exceeds -4 : 1000 mg sodium oxybate by direct intravenous injection bolus every hour at most until RASS score reaches -4.~Sedation maintained until patient death.
Study NCT05085873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: * Induction dosage : 1 mg every 3 min by direct intravenous injection until RASS score reaches -4 (with a maximum of 30 min).~* Continuous dosage : Half of titration dosage every hour by continuous intravenous injection.~* Additional dosage if the RASS score exceeds -4 : 1 mg every 3 min by direct intravenous injection (without exceeding 10 mg/h).~Sedation maintained until patient death.
Study NCT06219512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPET exercise prescription
Description: Exercise mode: walk Frequency: 5 times/week
Study NCT06219512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6MWT exercise prescription
Description: Exercise mode: walk Frequency: 5 times/week
Study NCT06219512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular exercise
Description: Regular exercise
Study NCT04814134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPNS Therapy
Description: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
Study NCT06662370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replacement of the esophagus with a decellularized human esophagus graft
Description: The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.
Study NCT06658678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receiving an educational intervention
Description: Patient not receiving any educational intervention
Study NCT06659198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total hip replacement
Description: minimally-invasive hip replacement
Study NCT06607380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002
Description: A single intramuscular (IM) gluteal injection
Study NCT06607380 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed tetanus vaccine
Description: A single IM deltoid injection
Study NCT06607380 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 + adsorbed tetanus vaccine
Description: A single IM gluteal injection+ a single IM deltoid injection
Study NCT04814134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Available standard treatment
Study NCT04814134 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Available standard treatment
Study NCT05438056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education with mobile application
Description: providing training to mothers of premature babies with a mobile application
Study NCT05077397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StO2
Description: InSpectra Tissue Spectrometer Model 1615 probe (Hutchinson Technology Inc. Hutchinson, MN, USA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices and StO2 values in the devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
Study NCT05077397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O3
Description: O3TM Regional Oximeter System (O3 System, Masimo Corporation, Irvine, CA) probes will be placed on the skin area corresponding to the patients' liver lodge prior to induction of anesthesia. In addition, the probes of both devices will be placed in the renal site on the same side. Basal values will be measured with both devices will be recorded every 15 minutes. Probes will not be removed during surgery and for 24 hours postoperatively.
Study NCT06334510 — intervention group
Intervention type: BIOLOGICAL
Intervention: One dose of quadrivalent influenza virus split vaccine was administered
Description: Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection.
Study NCT05230771 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palliative surgery after translational therapy
Description: A total, distal, or proximal gastrectomy with D1 lymph node dissection was done depending on tumour after translational therapy .~location.
Study NCT05230771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotheraoy along
Description: Patients receive only the prescribed chemotherapy.
Study NCT06422507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg aflibercept (BAY 86-5321) (High Dose)
Description: High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.
Study NCT06422507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg aflibercept (EYLEA, BAY 86-5321)
Description: Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye.
Study NCT06422507 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM).
Study NCT06606964 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
Study NCT06422507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM).
Study NCT05515536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Specified dose on specified days
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Specified dose on specified days
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Specified dose on specified days
Study NCT06425302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Specified dose on specified days
Study NCT05012683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Partial
Description: Patient is fit with Point Partial partial finger prosthetic system
Study NCT05680272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empathic communication-based education
Description: The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
Study NCT06442514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PASS-IVR
Description: An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.
Study NCT06442514 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Referral to the local smoking cessation VA clinic.
Study NCT05552716 — intervention group
Intervention type: OTHER
Intervention: School safety tactics and policies
Description: A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
Study NCT05033028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
Study NCT06566833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: self assmbling peptide p11-4 combined with 0.05% fluoride
Description: biomimetic remineralizing agent
Study NCT06566833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: remineralizing agents that acts as a fluoride booster
Study NCT06566833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% sodium fluoride varnish
Description: remineralizing agent that is used as a gold standard for remineralization
Study NCT05963698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN device
Description: Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
Study NCT05583617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.
Study NCT05583617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.
Study NCT05583617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Study NCT05583617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide will be administered PO on days 1-14 of a 21-day cycle.
Study NCT05583617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
Study NCT06287775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT06287775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tumor biopsy
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo optional tumor biopsy
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06287775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT06287775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06606964 — intervention group
Intervention type: OTHER
Intervention: Isokinetic Strength
Description: The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06287775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06287775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06556563 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Optune® device
Description: Optune® device delivering TTFields therapy at 200 kHz.
Study NCT06556563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune® device
Description: Optune® device delivering TTFields therapy at 200 kHz.
Study NCT06556563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide per approved labeling.
Study NCT06556563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide per approved labeling.
Study NCT06334471 — intervention group
Intervention type: OTHER
Intervention: no intervention needed
Description: no intervention needed
Study NCT04726592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorazepate Dipotassium
Description: Clorazepate Dipotassium : 20 mg intravenous injection
Study NCT04726592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV
Study NCT04726592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen 100 mg IV
Study NCT04693234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab
Description: Administered as specified in the treatment arm
Study NCT04693234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ociperlimab
Description: Administered as specified in the treatment arm
Study NCT04982887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
Study NCT06556563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Study NCT06556563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Study NCT06565572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nL-FLVC-001
Description: nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
Study NCT06249048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-001
Description: STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.